Literature DB >> 13950429

Creatinephosphokinase levels in hypothyroidism.

P D GRIFFITHS.   

Abstract

Entities:  

Keywords:  CREATINE KINASE; MYXEDEMA; THYROIDITIS, LYMPHOMATOUS

Mesh:

Substances:

Year:  1963        PMID: 13950429     DOI: 10.1016/s0140-6736(63)91676-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  SERUM ENZYME STUDIES IN MUSCLE DISEASE. II. SERUM CREATINE KINASE ACTIVITY IN MUSCULAR DYSTROPHY AND IN OTHER MYOPATHIC AND NEUROPATHIC DISORDERS.

Authors:  J M PEARCE; R J PENNINGTON; J N WALTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1964-04       Impact factor: 10.154

2.  SERUM LEVELS OF CREATINE PHOSPHOKINASE.

Authors:  P D GRIFFITHS
Journal:  J Clin Pathol       Date:  1964-01       Impact factor: 3.411

3.  [ON THE LOCALIZATION OF CREATINE KINASE (CK) IN MITOCHONDRIA AND MICROSOMES IN HUMAN SKELETAL MUSCLES, MYOCARDIUM AND CEREBRAL CORTEX].

Authors:  T O KLEINE
Journal:  Klin Wochenschr       Date:  1965-05-01

4.  Some Biochemical Aspects of the Myopathies.

Authors:  B P Hughes
Journal:  Postgrad Med J       Date:  1965-06       Impact factor: 2.401

5.  Benefits of short-term muscular training in reducing the effects of muscular over-exertion.

Authors:  R Seaman; C D Ianuzzo
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1988

6.  Serum enzymes in diseases of the thyroid gland.

Authors:  P D Griffiths
Journal:  J Clin Pathol       Date:  1965-09       Impact factor: 3.411

7.  Correlation between serum myoglobin and thyroid status in myasthenia gravis.

Authors:  W R Kiessling
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

8.  Severe myxoedema presenting with chondrocalcinosis and polymyositis.

Authors:  B E Mace; R K Mallya; J S Staffurth
Journal:  J R Soc Med       Date:  1980-12       Impact factor: 18.000

Review 9.  Rheumatism and the thyroid.

Authors:  D N Golding
Journal:  J R Soc Med       Date:  1993-03       Impact factor: 18.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.